Clinical Effect of Ampreloxetine (TD-9855) for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure

NCT03750552 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

195

Enrollment

INDUSTRY

Sponsor class

Conditions

Symptomatic Neurogenic Orthostatic Hypotension

Interventions

DRUG: ampreloxetine
DRUG: Placebo

Sponsor

Theravance Biopharma